[1]玉山江 ·艾克木,哈丽达·木沙,王晓腾,等.西红康对2型糖尿病肾病大鼠肾足细胞功能的影响[J].陕西中医,2023,(1):16-19.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.004]
　AIKEMU·Yushanjiang,MUSHA·Halida,WANG Xiaoteng,et al.Effects of Xihongkang on renal podocyte function in rats with type 2 diabetic nephropathy[J].,2023,(1):16-19.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.004]
点击复制

西红康对2型糖尿病肾病大鼠肾足细胞功能的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年1期
页码:
16-19
栏目:
基础研究
出版日期:
2023-01-05

文章信息/Info

Title:
Effects of Xihongkang on renal podocyte function in rats with type 2 diabetic nephropathy
作者:
玉山江 ·艾克木1; 哈丽达·木沙2; 王晓腾1; 郑 静1
(1.新疆医科大学附属中医医院干一科,新疆 乌鲁木齐 830054; 2.新疆医科大学第一附属医院干部综合科,新疆 乌鲁木齐 830011)
Author(s):
AIKEMU·Yushanjiang; MUSHA·Halida; WANG Xiaoteng; ZHENG Jing
(The Cadre Ward Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University,Urumqi 830054,China)
关键词:
2型糖尿病肾病;  西红康;  足细胞;  肾功能;  足突融合率;  肾小球基底膜平均厚度
Keywords:
Type 2 diabetic nephropathy;  Xihongkang;  Podocytes;  Renal function;  Fusion rate of foot process;  Average thickness of glomerular basement membrane
分类号:
R 587.2
DOI:
DOI:10.3969/j.issn.1000-7369.2023.01.004
文献标志码:
A
摘要:
目的:探讨西红康对2型糖尿病肾病大鼠肾足细胞功能的影响。方法:选择SPF级8周龄雄性Wistar大鼠50只大鼠随机分为空白对照组、DN模型对照组、西红康大剂量组、西红康中剂量组、西红康小剂量组,连续给药30 d后检测大鼠空腹血糖(FBG)、晚期氧化蛋白产物(AOPPs)与尿微量白蛋白(mALB)水平,各组大鼠在麻醉状态下取肾皮质,检测并比较足细胞计数、足突平均宽度、足突融合率及肾小球基底膜平均厚度。结果:干预30 d后,各剂量西红康治疗组与模型对照组比较,FBG、mALB与AOPPs水平均明显降低,差异具有统计学意义(P<0.05),但各剂量治疗组间比较差异无统计学意义(P>0.05)。各剂量西红康治疗组与模型对照组比较,足细胞计数、足突宽度、足突融合率与肾小球基底膜平均厚度(GBM)均明显增高或降低,差异具有统计学意义(P<0.05),西红康大、中剂量治疗组与小剂量治疗组比较,足细胞计数、足突宽度、足突融合率与GBM比较差异均具有统计学意义(P<0.05)。随着西红康剂量的增加,大鼠肾小球GBM增厚、足突断裂、排列不整齐、足突融合等现象明显减轻。结论:西红康可降低2型糖尿病肾病大鼠的FBG、AOPPs与mALB水平,还可有效改变其肾足细胞超微结构,达到保护肾脏的作用。
Abstract:
Objective:To investigate the effect of Xihongkang on renal podocyte function in rats with type 2 diabetic nephropathy.Methods:Fifty SPF 8-week-old male Wistar rats were randomly divided into blank control group,DN model control group,Xihongkang small,medium and high dose groups.After continuous administration for 30 days,the levels of FBG,AOPPs and mALB in the rats were detected.The renal cortex was taken from the rats in each group under anesthesia,and the podocyte count,the average width of the foot process,the fusion rate of the foot process and the average thickness of the glomerular basement membrane were detected and compared.Results:After 30 days of intervention,compared with the model control group,the levels of FBG,mALB and AOPPs in each dose of Xihongkang treatment group were significantly decreased,and the difference was statistically significant(P<0.05),but there were differences between the treatment groups at each dose no statistical significance(P>0.05).Compared with the model control group,the podocyte count,foot process width,foot process fusion rate and GBM in each dose of Xihongkang treatment group were significantly increased or decreased,and the difference was statistically significant(P<0.05).Compared with the low-dose treatment group,the podocyte count,foot process width,foot process fusion rate and GBM were significantly different in the dose treatment group(P<0.05).With the increase of the dose of Xihongkang,the rat glomerular GBM thickened,the foot process was broken,the arrangement was irregular,and the foot process fusion and other phenomena were obviously alleviated.Conclusion:Xihongkang can reduce the levels of FBG,AOPPs and mALB in rats with type 2 diabetic nephropathy,and can also effectively protect the kidneys from the ultrastructure of renal podocytes.

参考文献/References:

[1] Nagib AM,Elsayed MY,Gheith OA,et al.Diabetic nephropathy following posttransplant diabetes mellitus[J].Exp Clin Transplant,2019,17(2):138-146.
[2] Chen X,Sun L,Li D,et al.Green tea peptides ameliorate diabetic nephropathy by inhibiting the TGF-β/Smad signaling pathway in mice[J].Food Funct,2022,13(6):3258-3270.
[3] Luz MJ,Costa VAA,Balbi APC,et al.Effects of disodium cromoglycate treatment in the early stage of diabetic nephropathy[J].Focus on Collagen Deposition Biol Pharm Bull,2022,45(3):245-249.
[4] 玉山江·艾克木,哈丽达·木沙,地丽尼嘎尔.西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响[J].陕西中医,2020,41(3):338-341.
[5] Zhou T,Wang Y,Shen L,et al.Clinical and histological predictors of renal survival in patients with biopsy-proven diabetic nephropathy[J].Kidney Dis(Basel),2021,8(1):93-101.
[6] Fakhredini F,Mansouri E,Mard SA,et al.Effects of exosomes derived from kidney tubular cells on diabetic nephropathy in rats[J].Cell J,2022,24(1):28-35.
[7] Liao PY,Lo HY,Liu IC,et al.A gastro-resistant peptide from Momordica charantia improves diabetic nephropathy in db/db mice via its novel reno-protective and anti-inflammatory activities[J].Food Funct,2022,13(4):1822-1833.
[8] Khan MZ,Hussain M,Khan AA,et al.Frequency of non-diabetic renal disease in type 2 diabetes mellitus patients undergoing renal biopsy[J].J Ayub Med Coll Abbottabad,2021,33(4):s757-s762.
[9] Vlachou E,Ntikoudi A,Govina O,et al.Effects of probiotics on diabetic nephropathy:A systematic review[J].Curr Clin Pharmacol,2020,15(3):234-242.
[10] Zang L,Gao F,Huang A,et al.Icariin inhibits epithelial mesenchymal transition of renal tubular epithelial cells via regulating the miR-122-5p/FOXP2 axis in diabetic nephropathy rats[J].J Pharmacol Sci,2022,148(2):204-213.
[11] Zou H,Zhu S,Chen Y,et al.Kruppel like factor 5 enhances high glucose-induced renal tubular epithelial cell transdifferentiation in diabetic nephropathy[J].Crit Rev Eukaryot Gene Expr,2022,32(7):35-45.
[12] Ostergaard JA,Jha JC,Sharma A,et al.Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease[J].Clin Sci(Lond),2022,136(2):167-180.
[13] Cai L,Zhu H.Analysis of the improvement of serological indexes in patients with diabetic nephropathy and hypertension using Valsartan combined with Nifedipine controlled-release regimen[J].Pak J Med Sci,2022,38(6):1569-1574.
[14] 张 菁,姚 蔚,张进安,等.沙格列汀联合前列地尔治疗老年糖尿病肾病临床评价[J].陕西医学杂志,2020,49(12):1657-1660.
[15] 冯程程,玉山江.西红康治疗糖尿病肾病气阴两虚兼血瘀的疗效观察[J].临床合理用药杂志,2012,5(9):73-74.
[16] Chen YX,Zhu SY,Huang C,et al.LncRNA Dlx6os1 accelerates diabetic nephropathy progression by epigenetically repressing sox6 via recruiting EZH2[J].Kidney Blood Press Res,2022,47(3):177-184.
[17] Liao Q,Xu W,Luo Q,et al.Zhenqing recipe relieves diabetic nephropathy through the SIK1/SREBP-1c axis in type 2 diabetic rats[J].Am J Transl Res,2021,13(12):13776-13783.
[18] Ying C,Zhou Z,Dai J,et al.Activation of the NLRP3 inflammasome by RAC1 mediates a new mechanism in diabetic nephropathy[J].Inflamm Res,2022,71(2):191-204.
[19] Kaur P,Kotru S,Singh S,et al.Role of miRNAs in diabetic neuropathy:Mechanisms and possible interventions[J].Mol Neurobiol,2022,59(3):1836-1849.
[20] Jiang M,Lou XE,Zhang X,et al.Development and validation of the diagnostic scale of traditional Chinese medicine syndrome elements for diabetic kidney disease[J].Ann Palliat Med,2021,10(12):12291-12299.

相似文献/References:

[1]玉山江·艾克木,哈丽达·木沙△,地丽尼嘎尔.西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响*[J].陕西中医,2020,(3):338.
　Yushanjiang·Aikemu,Halida·Musha,Dilinigaer..Efficacy of adjuvant therapy of Xihongkang on type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on micro inflammation and antioxidant role[J].,2020,(1):338.

备注/Memo

备注/Memo:
基金项目:新疆维吾尔自治区自然科学基金资助项目(2021D01C218)
更新日期/Last Update: 2022-12-28